Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177996 · ClinicalTrials.gov registry record · Phase 4
Pharmacotherapy in Depression With Panic Spectrum
A Phase 4 study of Major Depression, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00177996: Completed Phase 4 study of Major Depression, sponsored by University of Pittsburgh.
NCT00177996 is a Phase 4 study of Major Depression that has completed, run by University of Pittsburgh. The registered enrollment target is 30 participants, below the 326-participant average among 28 other Major Depression trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00177996, a Phase 4 study of Major Depression, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is being conducted to find out if certain individuals benefit from taking medication for their depression with a low dose of the antidepressant medication Zoloft.
Primary Outcome
Scale to evaluate somatic and panic like symptoms
Conditions Studied
Interventions
- DRUG sertraline hydrochloride
Study Locations (1)
Pennsylvania
- Western Psychiatric Insititue and Clinic - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-10 |
| Est. Completion | 2007-01 |
| Phase | Phase 4 |
What the finished NCT00177996 record still lists
NCT00177996 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 326-participant average among 28 other Major Depression trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Major Depression appearing as the primary indexed condition, and to 1 intervention - of which sertraline hydrochloride is the first listed.
NCT00177996 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00177996 about?
NCT00177996 is a clinical study titled "Pharmacotherapy in Depression With Panic Spectrum". This research study is being conducted to find out if certain individuals benefit from taking medication for their depression with a low dose of the antidepressant medication Zoloft.
What is the current status of trial NCT00177996?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2001-10. Estimated completion is 2007-01.
What conditions does trial NCT00177996 study?
This clinical trial studies the following conditions: Major Depression.
What interventions are being tested in trial NCT00177996?
The interventions under investigation include: sertraline hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00177996?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00177996 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00177996's enrollment target sits among peer trials
30 22nd of 28 higher than 6 of 28 other Major Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.
COMPLETED · Phase 4
-
Preventing Depression Recurrence in Diabetes
COMPLETED · Phase 4
-
Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram
COMPLETED · Phase 4
-
Prozac Treatment of Major Depression: Discontinuation Study
COMPLETED · Phase 4
-
Thyroid Medication and Antidepressants for Treating Major Depression
COMPLETED · Phase 4
-
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia